Q-omics provides the consensus-scored NCMAP-DT profile across patient tissues and cancer cell-line models. NCMAP-DT expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, NCMAP-DT is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, NCMAP-DT RNA expression shows 10,169 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight HNSC, KIRC, and ESCA as cancer lineages where NCMAP-DT shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NCMAP-DT — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NCMAP-DT survival associations across molecular data types. NCMAP-DT RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NCMAP-DT RNA expression–survival associations across cancer types. High NCMAP-DT expression shows unfavorable associations in LUSC and DLBC, but favorable associations in HNSC, UCEC, SKCM and CHOL. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .006). Together, the overview and detailed table identify HNSC as the clearest survival context for NCMAP-DT RNA expression.
This table summarizes NCMAP-DT tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for NCMAP-DT. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NCMAP-DT shows lower tumor expression in KIRC, BRCA, THCA, KICH, KIRP and LUSC. The KIRC box plot shows higher NCMAP-DT RNA expression in normal versus tumor tissue (log2 FC = −0.149, t-test p < 0.001).
This table shows molecular features associated with NCMAP-DT in patient tissues and cancer cell lines. In patient samples, NCMAP-DT shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set.
